These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35959620)

  • 1. Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
    Robinson P; Coveñas R; Muñoz M
    Curr Med Chem; 2023; 30(16):1798-1812. PubMed ID: 35959620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
    Coveñas R; Rodríguez FD; Robinson P; Muñoz M
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
    Muñoz M; Coveñas R
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32962202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple Negative Breast Cancer: How Neurokinin-1 Receptor Antagonists Could Be Used as a New Therapeutic Approach.
    Muñoz M; Rosso M; Coveñas R
    Mini Rev Med Chem; 2020; 20(5):408-417. PubMed ID: 31721701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
    Shi Y; Wang X; Meng Y; Ma J; Zhang Q; Shao G; Wang L; Cheng X; Hong X; Wang Y; Yan Z; Cao Y; Kang J; Fu C
    Adv Sci (Weinh); 2021 Nov; 8(21):e2101936. PubMed ID: 34605226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the research and application of neurokinin-1 receptor antagonists.
    Hong X; Ma J; Zheng S; Zhao G; Fu C
    J Zhejiang Univ Sci B; 2024 Feb; 25(2):91-105. PubMed ID: 38303494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.
    Martín-García D; Téllez T; Redondo M; García-Aranda M
    Curr Med Chem; 2024; 31(39):6487-6509. PubMed ID: 37861026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of NK-1R using aprepitant suppresses inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes.
    Liu X; Zhu Y; Zheng W; Qian T; Wang H; Hou X
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1628-1634. PubMed ID: 31010320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia.
    Muñoz M; Coveñas R
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32492831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
    Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
    Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists.
    Muñoz M; González-Ortega A; Rosso M; Robles-Frias MJ; Carranza A; Salinas-Martín MV; Coveñas R
    Peptides; 2012 Dec; 38(2):318-25. PubMed ID: 23026680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.
    Muñoz M; Rosso M
    Invest New Drugs; 2010 Apr; 28(2):187-93. PubMed ID: 19148578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
    Munoz M; Covenas R; Esteban F; Redondo M
    J Biosci; 2015 Jun; 40(2):441-63. PubMed ID: 25963269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
    Hesketh PJ; Van Belle S; Aapro M; Tattersall FD; Naylor RJ; Hargreaves R; Carides AD; Evans JK; Horgan KJ
    Eur J Cancer; 2003 May; 39(8):1074-80. PubMed ID: 12736106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of neurokinin-1 receptor antagonists.
    Muñoz M; Coveñas R
    Expert Opin Drug Saf; 2013 Sep; 12(5):673-85. PubMed ID: 23706125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.
    Muñoz M; González-Ortega A; Salinas-Martín MV; Carranza A; Garcia-Recio S; Almendro V; Coveñas R
    Int J Oncol; 2014 Oct; 45(4):1658-72. PubMed ID: 25175857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients.
    Robinson P; Rosso M; Muñoz M
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression.
    Mohammadi F; Javid H; Afshari AR; Mashkani B; Hashemy SI
    Mol Biol Rep; 2020 Jun; 47(6):4263-4272. PubMed ID: 32436041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis.
    Martinez AN; Burmeister AR; Ramesh G; Doyle-Meyers L; Marriott I; Philipp MT
    J Neuroinflammation; 2017 Feb; 14(1):37. PubMed ID: 28202084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
    Muñoz M; González-Ortega A; Coveñas R
    Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.